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Aims: To evaluate the performance of the RETeval device, a handheld instrument using ﬂicker
electroretinography (ERG) and pupillography on undilated subjects with diabetes, to detect vision-
threatening diabetic retinopathy (VTDR).
Methods: Performance was measured using a cross-sectional, single armed, non-interventional, multi-site
study with Early Treatment Diabetic Retinopathy Study 7-standard ﬁeld, stereo, color fundus photography as
the gold standard. The 468 subjects were randomized to a calibration phase (80%), whose ERG and pupillary
waveforms were used to formulate an equation correlating with the presence of VTDR, and a validation phase
(20%), used to independently validate that equation. The primary outcomewas the prevalence-corrected area
under the receiver operating characteristic (ROC) curve for the detection of VTDR.
Results: The area under the ROC curve was 0.86 for VTDR.With a sensitivity of 83%, the speciﬁcity was 78% and
the negative predictive value was 99%. The average testing time was 2.3 min.
Conclusions:With a VTDR prevalence similar to that in the US, the RETeval device will identify about 75% of the
population as not having VTDR with 99% accuracy. The device is simple to use, does not require pupil dilation,
and has a short testing time.© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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c. This is an open access article under1. Introduction
Diabetic retinopathy (DR) remains the leading cause of blindness
among working age adults in the US (American Academy of
Ophthalmology Retina/Vitreous Panel, 2014; Centers for Disease
Control and Prevention, 2011) and is a major cause of blindness
worldwide (Yau et al., 2012). In the US, less than 50% of the patients
with diabetes receive an annual DR examination (Lee, Feldman,
Ostermann, Brown, & Sloan, 2003; Lee et al., 2014; Paz et al., 2006;
Rosenberg, Friedman, & Gurland, 2011; Saadine, Fong, & Yao, 2008).
Many of those with vision-threatening diabetic retinopathy (VTDR)
(Zhang et al., 2010) are not diagnosed in time to beneﬁt from the
remarkable efﬁcacy of DR therapy established by the Diabetic
Retinopathy Study (DRS) (Ferris, 1993), Early Treatment Diabetic
Retinopathy Study (ETDRS) (ETDRS Research Group, 1991a; Chew et
al., 2003) and clinical trials of intravitreal anti-VEGF therapy (Brownthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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deﬁned as severe non-proliferative or proliferative DR, with or
without clinically signiﬁcant macular edema (CSME) (American
Academy of Ophthalmology Retina/Vitreous Panel, 2014; Zhang et
al., 2010). Patients with VTDR are at risk for blindness or moderate
vision loss and should be referred to an eye care provider.
This study reports the performance characteristics of the RETeval
device to identify subjects with VTDR. ETDRS 7-standard ﬁeld, stereo,
color fundus photography, read by a qualiﬁed reading center was the
gold standard (Ku, Landers, Henderson, & Craig, 2013; Lawrence,
2004; Williams et al., 2004) for comparison. Unlike ophthalmoscopy
and retinal photography, the RETeval device combines ﬂicker
electroretinogram (ERG) and pupillary responses to generate a single
numerical output that can be compared to a cutoff value in order to
minimize the subjectivity of testing for VTDR.
The ERGmeasures the electrical activity of the retina in response to
an intermittent ﬂash stimulus (McCulloch et al., 2015). The ﬂicker ERG
waveform is typically characterized by a time delay between the light
stimulus and the peak electrical response (implicit time), and the
peak-to-peak amplitude of the electrical response. The ﬂicker ERG is a
response from the cone system, and is therefore representative of the
whole retina. While anatomical studies (Curcio, Sloan, Kalina, &
Hendrickson, 1990) show a 40-fold increase in cone density in the
fovea, the area of the fovea is quite small (3.6 mm2 out of 1000 mm2)
and the rest of the retina is relatively uniform in cone density. Changes
in these ERG parameters correlate strongly with DR severity (Bresnick
& Palta, 1987; Han & Ohn, 2000; Holopigian, Seiple, Lorenzo, & Carr,
1992; Kim, Lee, Bae, Cho, & Kang, 1997; Messias et al., 2012; Park, Sun,
Lee, Park, & Ohn, 2010; Satoh, Iijima, Imai, Abe, & Shibuya, 1994; Tahara,
Matsuura, & Otori, 1993; Tyrberg et al., 2011). DR progression leads to
increasing retinal ischemia (American Academy of Ophthalmology
Retina/Vitreous Panel, 2014) which prolongs the implicit time and
decreases the amplitude (Park et al., 2010; Satoh et al., 1994; Severns
& Johnson, 1993).
The pupillary response to a light stimulus has also been shown to
correlate with DR severity (Nakayama et al., 2001; Ortube et al., 2013;
Smith & Smith, 1983; Straub, Jeron, & Kerp, 1992; Straub, Thies, Jeron,
Palitzsch, & Scholmerich, 1994). Both the rate and extent of pupil
constriction in response to a light stimulus decrease with increasing DR
severity (Ortube et al., 2013).
The objectives of this study were ﬁrst to determine the best
method of combining ERG and pupillary response measurements for
the detection of VTDR, and second to evaluate the performance using
an independent cohort of subjects.
2. Materials and methods
2.1. RETeval device
The handheld RETeval device (LKC Technologies Inc., Gaithersburg,
MD; Welch Allyn, Inc., Skaneateles Falls, NY), simultaneously
measures the full-ﬁeld ﬂicker ERG and pupillary response to light
(Kato, Kondo, Sugimoto, Ikesugi, & Matsubara, 2015). A 28.3 Hz
ﬂickering white-light stimulus (CIE 1931 chromaticity of 0.33, 0.33) is
produced by brief (b5 ms) ﬂashes from red, green, and blue LEDs in a
ganzfeld (i.e., an integrating sphere). The ganzfeld also has a red ﬁxation
LED to direct the subject’s gaze during the test. The device has an
IR-sensitive camera and an IR LED to video the eye in the infrared at the
ﬂicker frequency. The pupil size is measured in real-time from the video.
The timing among the stimulus, data acquisition, and video recording are
hardware-synchronized through the use of a single clock crystal. The
pupillary measurements are used to dynamically adjust the white light
stimulus according to the formula ﬂash retinal illuminance (Troland·
second or Td·s) = ﬂash luminance (cd·s/m2) × pupil area (mm2),
thereby providing an ERG stimulus that is largely independent of pupil
size (Kato et al., 2015). A sensor strip skin electrode, which has separatepatches for a positive, negative, and an active ground (right leg drive)
contact,wasplacedbeloweach lower eyelid (Kato et al., 2015).While skin
electrodes have traditionally been avoided in ERG testing due to lower
signal levels (McCulloch et al., 2015), improvements in hardware data
acquisition and Fourier-based analysis methods have enabled the
reproducible results described in this study while avoiding the need to
touch the eye with corneal electrodes. The pupils are not artiﬁcially
dilated, so that the device can use the pupillary response as an
independent indicator of DR severity.2.2. Study design
To ensure representation of all levels of disease, subjectswith diabetes
were selectively recruited, via chart review, to tentatively targetoneofﬁve
DR severity strata (ETDRSResearchGroup, 1991b;Wilkinson et al., 2003).
The severity strata were (1) no DR, (2)mild non-proliferative DR (NPDR)
without clinically signiﬁcantmacular edema (CSME), (3)moderate NPDR
without CSME, (4) mild or moderate NPDR with CSME, and (5) severe
NPDR or proliferative DR with or without CSME.
This multi-site, non-interventional study was cross-sectional and
had a single arm. In a single session, each subject was ﬁrst tested with
the RETeval device followed by an Amsler grid psychophysical test.
The Amsler grid is used to detect metamorphopsia, a change in the
perceived shape of objects that implies macular edema or other
macular pathology. A randomly selected subset was retested with the
RETeval device to assess test–retest variability. The subjects were then
dilated with tropicamide and phenylephrine drops. After dilation,
subjects underwent ETDRS 7-standard ﬁeld, stereo, color fundus
photography, which completed their participation in the study.
The RETeval device tested each eye with 4, 8, 16, and 32 Td·s ﬂicker
stimuli (28.3 Hz) that each lasted between 5 and 15 s, depending on the
standard error of mean for the implicit time measurement. There was no
background light, as previous studies have shown improved detection of
VTDR without a background light (Bresnick & Palta, 1987; Tyrberg et al.,
2011). The stimuli were presented in randomized order, with about 1 s of
darkness between each brightness tested. The brightness of the stimuli
was selected to maintain subject comfort while providing a large enough
response to have good signal to noise ratio.
The subject’s ETDRS 7-standard ﬁeld images were double graded
by readers masked to the other readers’ results and to the RETeval
results, in a dedicated reading center (Inoveon Corp, Oklahoma City,
OK). Results differing by more than one ETDRS level (ETDRS Research
Group, 1991b) or with respect to the VTDR referral criterion, were
adjudicated by the two readers overseen by a retinal specialist. The
adjudicated results for the subject’s worst eye (because in clinical
practice subjects, not individual eyes, are referred for evaluation by an
eye care provider) served as the gold standard to which the RETeval
device results were compared.
Technical failures from ungradeable ETDRS 7-standard ﬁeld photo-
graphs created two more DR severity strata: CSME with ungradable DR
severity, and ungradable CSME and DR severity. For a subject to be
considered ungradable, either both eyes were ungradable or one eye was
ungradable while the other did not have VTDR. Subjects with ungradable
ETDRS photographs were excluded by necessity from further analysis.
Subjects with ungradable RETeval results were considered to have tested
positive for VTDR, as is done in screening programs in order to reduce the
likelihood of false negatives (Castell, 2012).
At theendof the trial, subjectswere randomized toacalibrationportion
and validation portion that were separately analyzed, as described below.
The research followed the tenets of the Declaration of Helsinki;
informed consentwas obtained from the subjects after explanation of the
nature and possible consequences of the study; and the institutional
review boards of the participating institutions approved the research. The
studywas overseen by an independent studymonitor and is registered at
ClinicalTrials.gov (NCT01950663).
526 A.Y. Maa et al. / Journal of Diabetes and Its Complications 30 (2016) 524–5322.3. Subjects
468 subjects were enrolled at two centers in the United States
(Atlanta VA Medical Center and Oklahoma City VA Medical Center).
The enrollment target was 80 subjects in each of the ﬁve DR severity
strata. Inclusion criteria were that subjects be diagnosedwith diabetes
and treated with at least one oral hypoglycemic medication or insulin.
Exclusion criteria were (1) a history of photosensitive epilepsy, (2)
previous laser or drug treatment for DR or CSME, (3) eye diseases
other than diabetic retinopathy or macular edema that, in the opinion
of the recruiting ophthalmologist, might affect the ERG or result in
ungradable ETDRS photographs, (4) or an inability or unwillingness of
the subject or legal representative to provide written informed
consent. Previous laser or drug treatment for DR or CSME was an
exclusion criteria because we wanted to target subjects who did not
know if they had VTDR under the assumption that those people who
knew they had VTDR were already receiving adequate care.
2.4. Outcomes
The primary outcome was the area under the receiver operating
characteristic (ROC) curve for the detection of VTDR in either eye.
VTDR is severe non-proliferative (ETDRS level 53) or proliferative
(ETDRS levels 61–85) DR or the presence of CSME with any ETDRS
level (American Academy of Ophthalmology Retina/Vitreous Panel,
2014; Zhang et al., 2010). In the calibration and validation portions of
the analysis, the area under the ROC curve (AUROC) was not adjusted
for the intentional oversampling of DR severity strata. However, a ﬁnal
ROC analysis did correct for the intentional oversampling. These
calculations used prevalence data from a commercial ETDRS 7-standard
ﬁeld diabetic retinopathy evaluation service on 55,000 right eyes from
subjects’ ﬁrst visits over the past decade (Inoveon Corp, Oklahoma City,
OK). These data, shown in Table 1, were used for the prevalence
correction because, to our knowledge, prevalence data for the six DR
severity strata used in this study have not been published.
2.5. Sample size
The sample size for this study was based on comparison of paired
AUROCcurvesandconﬁdence intervalwidthswith90%powerassuminga
5% two-sided alpha error. We assumed the correlation between two
measurements of the same person is 0.5. While during the calibration
phase of the trial many such comparisons would be made, there was no
adjustment for alpha error inﬂation because any such error would be
caught during the validation phase. Validation was based on an
independent cohort of subjects that were assessed only once.
2.6. Reproducibility
A 30% random sample of subjects was selected for retesting to
assess RETeval device test–retest variability. Study personnel were
not informed if a subject was selected for retesting until after the ﬁrst
RETeval test and the Amsler grid test had been performed.Table 1
Severity groups.
International Clinical Classiﬁcation
(Wilkinson et al., 2003)
ETDRS Level CSME Calibration
(N = 371)
No NPDR 10–12 − 74
Mild NPDR 14–35 − 101
Moderate NPDR 43–47 − 72
CSME with No, Mild, or Moderate NPDR 10–47 + 31
Severe NPDR or Proliferative DR 53–85 +/− 41
Ungradable ETDRS Level ? + 12
Ungradable fundus photographs ? ? N/A2.7. Statistical methods
Following dataset closure, measurements from 80% of the subjects
in each disease severity groupwere randomly selected to calibrate the
RETeval’s detection algorithm, while 20%were reserved for validation.
2.7.1. Calibration phase
The purpose of the calibration phase was to determine the best
way to combine the information obtained by the RETeval device to
predict the presence of VTDR as determined by the gold standard.
The measurements used in the analysis included the amplitude and
implicit time for eachERGbrightness (bothasusing thewholewaveformand
just the fundamental of the waveform as suggested in the literature as being
more robust (McAnany & Nolan, 2014; Severns, Johnson, & Merritt, 1991)).
Thepupillaryresponseused intheanalysiswastheratioof thepupilarea from
the 32 Td·s and the 4 Td·s stimuli after the initial 2.5 s of the stimulus. The
brightnessof the iris in the infrared imageswasalsousedasameasurement in
the analysis, as it had been reported that blue irides are relatively transparent
and don’t attenuate pupillary responses (Kardon, Hong, & Kawasaki, 2013).
The inﬂuence of age on RETeval measurements was assessed by using
the 74 subjects in the calibration phase with no DR in either eye (ETDRS
level 10), none of whom had CSME in either eye. This group was used for
age correction so as to not confound changes in DR disease state with age
while still using a relevant population (subjects with diabetes) to
determine the age dependencies. Ages in this group ranged from 23 to
77 years (mean = 59.7, SD = 10.8). Measurements for the two eyes of
each subject were averaged and ﬁt using linear regressionmodels of each
parameteronto age.Residualplotswere examined to assess fornon-linear
effects and none were noted.
Age-corrected measurements from the two eyes of each subject were
characterized as either best eye (BE) or worst eye (WE). These best eye and
worsteyedeviationswere included intoaforwardstepwise logistic regression
model with referral (yes/no) as the dependent variable. The criterion for
inclusion of a parameter into the forward stepwise logistic regressionmodel
was a p-value of 0.01 by the likelihood ratio method; this criterion, more
stringent than theusual 0.05p-value,was selected tominimizeover-ﬁttingof
the predictionmodel to the calibration dataset. Model coefﬁcientswere used
to create a prediction equation andapredictionprobabilitywas generated for
each subject in the calibration stage. The prediction probability was in turn
used to create the numerical output of the RETeval device.
By varying a cutoff value abovewhich subjects are considered to have
tested positive for VTDR (and therefore referred), a Receiver Operating
Characteristic (ROC) curve was constructed and the area under the curve
and its asymptotic 95% conﬁdence interval were determined.
2.7.2. Validation phase
The prediction equation was then applied to the 20% validation
sample. An ROC curve was generated, and the area under the curve
and its asymptotic 95% conﬁdence interval were similarly determined.
2.7.3. Application to primary care prevalence
These analyses include all subjects measuredwith the RETeval device,
excluding those that could not be assessed with ETDRS 7-standard ﬁeld
photography. Because the area under the ROC curve (AUROC) in thephase Validation phase
(N = 96)
Application to primary care
prevalence (N = 467)
Primary care
prevalence
19 93 (20%) 74.2%
26 127 (27%) 20.1%
18 90 (19%) 2.5%
8 39 (8%) 0.8%
11 52 (11%) 2.3%
3 15 (3%) 0.5%
N/A 51 (11%)
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inclusion of all subjects should not lead to an overly optimistic estimate of
RETeval performance in a primary care setting. Thus, all subject datawere
used to generate an ROC curve after prevalence-correcting the results
using the data shown in Table 1. The area under the ROC curve was
generated asymptotically, and a bootstrap method was used (1000
replicates) for the conﬁdence interval.
The prevalence-corrected referral statistics for a variety of prediction
probabilities were computed. The positive and negative predictive values
were based on the prevalence of vision-threatening diabetic retinopathy
in theUS(4.4%) (Zhanget al., 2010). If theworldwideprevalencewasused
(10.2%) (Yauet al., 2012), theNPVswouldbe lowerand thePPVswouldbe
higher. The lower conﬁdence limit (LCL) andupper conﬁdence limit (UCL)
of the 95% conﬁdence interval were computed from the Clopper–Pearson
interval for binomial distributions.
Reproducibility was determined using the intraclass correlation
(ICC). A widely used guide to interpreting ICCs (Fleiss, 1981)
characterizes ICC b 0.4 to be poor reproducibility, ICC N 0.75 excellent
reproducibility, and ICC from 0.4 to 0.75 as fair to good.3. Results
3.1. Subject ﬂow
A total of 468 subjects were enrolled between September 2013 and
April 2014; 467 completed testing (99.8%). The subject who did not
complete the study left after being tested with the RETeval device, the
Amsler grid, and after being dilated but before ETDRS 7-standard ﬁeld
photography. Recruitment ended after the study sites exhausted their
pool of potential subjects in the low prevalence categories that had fewer
than 80 subjects. For reproducibility, 137 subjects were randomly
assigned to duplicate the RETeval test; data were missing for 9 of those
subjects (6weremissingdue toprocedural issuesunrelated to theRETeval
device and 3 were missing due to RETeval device technical failures).3.2. Subject characteristics
Thecharacteristicsof the subjects are shown inTable2. Thepercentage
of female subjects in the study (12.4%) was substantially greater than the
percentage of female users of the VHA health care system (5%).Table 2
Subject characteristics.
Characteristic Calibration phase
(N = 371)
Validation phase
(N = 96)
Age (yr)
Mean (SD) 60 (10) 61 (12)
Range 23–88 24–82
Race, no. (%)
Caucasian 193 (52%) 50 (52%)
African American 147 (40%) 37 (39%)
Native American 19 (5%) 5 (5%)
Hispanic 6 (2%) 3 (3%)
Other 4 (1%) 1 (%)
Asian 2 (0.5%) 0 (%)
Gender, no. (%)
Female 48 (13%) 10 (10%)
Male 323 (87%) 86 (90%)
Diabetes type, no. (%)
1 17 (5%) 5 (5%)
2 354 (95%) 91 (95%)
Medication type, no. (%)
Oral 121 (33%) 28 (29%)
Insulin 119 (32%) 31 (32%)
Both 131 (35%) 37 (39%)
a 2-sample t-test.
b chi-squared test.
c Fisher exact test.3.3. Outcomes
Fig. 1 shows representative ERG and pupillary data for a subject with
andwithout VTDR,while Fig. 2 shows summary statistics for all subjects. In
the presence of VTDR, the best eye’s 32 Td·s ERG timing is delayed, the best
eye’s 16 Td·s ERG amplitude is reduced, and the worst eye’s pupillary
response (4 Td·s compared to 32 Td·s) is reduced. These three parameters
(age-corrected) were all highly statistically signiﬁcantly associated with
referral status (p ≤ 0.002), and formed the prediction equation used to
generate the RETeval device’s numerical output (called DR Score in Fig. 2).
Fig. 3 shows the receiver operating characteristic curves from the
calibration phase, validation phase, and the overall result utilizing the
prevalence found inprimary care settings. Theareaunder the curve for the
validation (0.81; 95% conﬁdence interval of 0.71–0.92) is larger than that
of the calibration (0.78; 95% conﬁdence interval of 0.72–0.84), giving
assurance that thepredictionequationgeneratedwith the calibrationdata
was not over-ﬁtted to peculiarities of those data. The stratiﬁed
recruitment strategy employed in this trial created a population that
was heavily concentrated with cases near the VTDR threshold which was
useful to calibrate thedevice tobestdistinguishVTDRbyoversampling the
casesmostdifﬁcult to categorize.After correcting to theprevalence seen in
a primary care setting, the area under the curve increased (0.86; 95%
conﬁdence interval of 0.77–0.93).
Table 3 shows the performance of the RETeval device for detecting
VTDR at 5 points along the prevalence-corrected ROC curve of Fig. 3. For
example, with a cutoff value of ≥20, the device has a sensitivity of 83%, a
speciﬁcity of 78%, and a negative predictive value of 99% for VTDR. In a
primary care setting, for every 1000 subjects tested, about 44 will have
VTDR. With a cutoff of ≥20, it is expected that about 753 subjects will be
below the referral threshold, 7 of whom will have VTDR. Of the 247
referred, 37 will have VTDR. Thus the device should eliminate over
three-fourths of the tested population while missing very few cases. By
lowering the referral threshold, the negative predictive value can be
improved at the expense of more subjects referred for further testing. For
example, with a cutoff of ≥17.6 the negative predictive value is 99.5%. For
every 1000 subjects tested it is expected that about 500 (half) will be
below the referral threshold, only 3 of which would have VTDR.
Among the 93 subjects with no retinopathy or CSME, there was no
statistically signiﬁcant difference in the mean RETeval result between
either genders (p = 0.44, 2 sample t-test) or between Caucasians and
African Americans (p = 0.28, one way ANOVA).Application to primary care
prevalence (N = 467)
P-value between calibration
and validation phases
0.39a
61 (11)
23–88
243 (52%) 0.92b
184 (39%)
24 (5%)
9 (2%)
5 (1%)
2 (0.4%)
0.60c
58 (12%)
409 (88%)
0.79c
22 (5%)
445 (95%)
0.78b
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150 (32%)
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Fig. 1. Representative raw data from the RETeval device from two subjects, one with and one without VTDR. The top plot shows the timing difference between the subject with VTDR
(red line) and the subject without VTDR (blue line) for the 32 Td·s ﬂicker ERG. In this steady-state response, the ﬂashes occurred at time = 0, ±35.33 ms, ±70.66 ms, etc. The
vertical grid lines show the implicit time between the ﬂash and the eye’s peak electrical response to be about 30 ms for the subject without VTDR, faster than the 38 ms for the
subject with VTDR. The middle plot shows the amplitude difference for the 16 Td·s ﬂicker ERG, where the horizontal grid lines show the peak-to-peak amplitude for the subject
without VTDR was 26 μV, larger than the 23 μV for the subject without VTDR. The bottom plots show the difference in pupillary response between a 4 Td·s and 32 Td·s ﬂickering
stimulus for the subject with VTDR (bottom left) and without VTDR (bottom right). The time scale for the pupillary response is from the onset of the ﬂickering light (0 s) to 5 s. The
grid lines show that after initial transients, the pupil size for the subject with VTDR was 2.45 mmwith the brighter 32 Td·s ﬂicker stimulus, and was a slightly larger 2.66 mm with
the dimmer 4 Td·s ﬂicker stimulus. The subject without VTDR had a larger change in pupil diameter between the two stimuli: 3.10 mm vs 1.89 mm. These changes in pupil size are
summarized by the ratio of the pupil areas. The subject without VTDR had a pupil area ratio of 2.7 (=3.102/1.892), larger than the 1.2 for the subject with VTDR.
528 A.Y. Maa et al. / Journal of Diabetes and Its Complications 30 (2016) 524–532Using the results of the Amsler grid test did not improve the
RETeval device’s performance of detecting VTDR.
3.4. Ancillary analyses
3.4.1. Testing time
RETeval testing time averaged 2.3 min (standard deviation,
0.8 min) to test both eyes.
3.4.2. Reproducibility
Using the 128 subjects with duplicate RETeval measurements, the
test–retest standard deviation was 1.25 and the intraclass correlation
(ICC) was 90.2%. Thus, the RETeval device measurements haveexcellent reproducibility (Fleiss, 1981). The RETeval measurements
in this group ranged from 11.1 to 31.8, with a mean of 19.7.3.4.3. Performance excluding CSME
If CSME is ignored in the primary-care prevalence analysis, the
RETeval device’s performance is improved, having a sensitivity of 87%,
a speciﬁcity of 78%, and a negative predictive value of 99.2% with a
cutoff of ≥20. For every 1000 subjects tested, 752 would not be
referred, 6 of which have severe NPDR or PDR. In the 248 referred, 38
will have severe NPDR or PDR. By lowering the referral threshold, to a
cutoff of ≥17.9, the sensitivity is 94%, speciﬁcity is 54%, and the
negative predictive value is 99.5%.
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Fig. 2. Dependence of RETeval measurements on diabetic retinopathy severity level. Plots show the mean and standard error of the mean for three measurements and the overall
RETeval measurement (DR Score) for each severity group. Severity group deﬁnitions and the number of subjects in each group can be found in Table 1. BE andWE stand for “best eye”
and “worst eye” respectively.
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The RETeval device had a technical failure rate (no results
generated) of 1% (5/467) whereas ETDRS 7-standard ﬁeld photogra-
phy (ungradable images) had a signiﬁcantly higher (P b 0.001, exact
McNemar test) technical failure rate of 11% (51/467). The RETeval
device generated results on 98% (50/51) of the subjects who had
ungradable ETDRS photographs.
3.5. Safety
No adverse events were reported.
4. Discussion
Using a cutoff score of 20.0, our analysis (Table 3) suggests that if
100 unselected subjects with diabetes are tested with the RETeval
device, 76 will have a negative test result and of those 75 (99%) willnot have VTDR. Therefore, over three fourths of the subjects will be
told they do not have VTDR with 99% accuracy. This allows providers
to focus on the remaining 24 who may have VTDR or another ocular
disease that requires attention. Test time averaged 2.3 min in this
study. The device had a technical failure rate of 1%. This combination
of accuracy and efﬁciency should improve the quality and cost-
effectiveness of DR testing and compliance. In comparison to earlier
ERG studies and pupillary response studies, this study shows
improved performance in part due to the combination of these
formally disparate measures into a combined score, which to the
authors’ knowledge has not been done before.
The RETeval device’s performance compares favorably to point of care
digital retinal photography when using ETDRS 7-standard ﬁeld photog-
raphy as the gold standard. One point of care digital retinal imaging
system (Joslin VisionNetwork, Boston,MA) photographed 3 stereoscopic
nonmydriatic ﬁelds and reported a sensitivity of 85% and speciﬁcity of
100% for the detection of severe NPDR orworse in the subject’sworst eye
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Fig. 3. Receiver operating characteristic (ROC) curves for the calibration phase,
validation phase, and prevalence-corrected overall result. The cutoff values from Table
3 are labeled on the prevalence-adjusted curve.
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(87%), and worse speciﬁcity (78%) when using the same criteria. The
digital retinal imaging system did not report performance when CSME is
included; nonetheless, subjects with CSME should be included in these
analyses if the results are used to identify subjects at risk for vision loss
(American Academy of Ophthalmology Retina/Vitreous Panel, 2014).
While this photographic system takes stereo photographs and therefore
can inprinciplemeasureCSME,manyphotographysystemsarenot stereo
and therefore cannot directly assess macular edema.
The RETeval device's technical failure rate (1%) was much better than
that reported for the digital retinal imaging system (35%) (Ahmed et al.,
2006). If subjects with ungradeable images are referred, the speciﬁcity of
thedigital retinal imaging systemdecreases from100% to66%whenusing
a disease prevalence of 4.4% (Zhang et al., 2010). Thus, the RETeval
device’s sensitivity and speciﬁcity compare favorably to nonmydriatic
digital retinal imagingwhen subjectswithungradable images are referred
and included in the performance analysis.Table 3
Performance metrics with the primary care prevalence.
RETeval
cutoff
value
Sensitivity Speciﬁcity Predictive Power
of Test
Percent of Tested Sample
Positive
Test
Negative
Test
Positive Negative True False True False
17.6 93% 52% 8% 99.5% 4.1% 46% 50% 0.2%
LCL 73% 47% 5% 97% 2.4% 41% 45% 0.0%
UCL 99.9% 57% 13% 100.0% 6.5% 51% 55% 1.3%
18.1 90% 57% 9% 99.2% 3.8% 41% 55% 0.5%
LCL 65% 52% 5.0% 97% 2.2% 36% 50% 0.1%
UCL 99% 62% 14% 99.9% 6.2% 46% 59% 1.7%
19.1 88% 67% 11% 99.1% 3.8% 31% 64% 0.5%
LCL 65% 62% 6% 97% 2.2% 27% 59% 0.1%
UCL 99% 72% 17% 99.9% 6.2% 36% 69% 1.7%
20.0 83% 78% 15% 99% 3.6% 21% 75% 0.7%
LCL 59% 74% 9% 97% 2.0% 17% 71% 0.1%
UCL 96% 82% 23% 99.9% 5.9% 25% 79% 2.1%
21.2 73% 84% 17% 99% 3.1% 15% 80% 1.2%
LCL 47% 80% 9% 97% 1.7% 12% 76% 0.4%
UCL 90% 87% 27% 99.5% 5.3% 19% 84% 2.8%
LCL and UCL represent the lower and upper 95% conﬁdence limits, respectively.The RETeval device’s performance also compares favorably to
ophthalmologists when using ETDRS 7-standard ﬁeld photography as
the gold standard. In one large study (Pugh et al., 1993) (n = 352),
ophthalmologists performed indirect ophthalmoscopy followed by either
direct ophthalmoscopy or slit lamp biomicroscopy to classify each
subject’s worst eye as positive (moderate to severe NPDR or PDR) or
negative. Two retina specialists and eight general ophthalmologists
performed the examinations. The study did not report performance
when CSME is included. The ophthalmologists’ sensitivity was 33% and
speciﬁcity was 99%.
Table 4 summarizes the results of these studies, all of which used
the ETDRS 7-standard ﬁeld photography gold standard. The sensitivity
and speciﬁcity are those described above. The remaining metrics
assume a VTDR prevalence of 4.4% (Zhang et al., 2010). The RETeval
device has the smallest number of false negatives, the most important
factor from an initial detection point of view.
4.1. Limitations
Several demographic characteristics of the subjects enrolled in this
study differed from the US population. Although 58 female subjects were
enrolled, study subjectswere predominantlymale Caucasians andAfrican
Americans. Although this could affect generalizability, we saw no
statistically signiﬁcant difference in the mean RETeval results between
genders or between those two races in our no-retinopathy group.
Subjects with concurrent eye disease that could affect the ERG
(e.g., retinal vascular occlusive disease (Severns & Johnson, 1993;
Yasuda, Kachi, Ueno, Piao, & Terasaki, 2015; Kjeka, Jansson, Bredrup, &
Krohn, 2013; Larsson, Bauer, & Andreasson, 2000)) were excluded
from this study to avoid confounding the results. These diseases have
a similar effect on the ERG and therefore are likely to cause a false
positive result. When testing unselected subjects, as would be done in
practice, these “false positive” subjects would actually improve the
negative predictive value of the test. The positive predictive value
would decrease although these “false positive” subjects likely have an
eye disease and would beneﬁt from referral to an eye care provider.
5. Conclusions
The RETeval device offers a new approach for DR testing. Validated
using gold standard ETDRS 7-standard ﬁeld photography, this
handheld device measures the eye’s electrical and pupillary responses
rather than photographing the retina. The beneﬁts of this method
include no dilation, short test time, minimal personnel training,
immediate results, and low technical failure rates. The ﬂicker ERG is
largely unaffected by cataracts (Ratanapakorn et al., 2010) and theTable 4
Detection of severe NPDR or PDR using ETDRS 7-standard ﬁeld stereo photography as
the gold standard in a subject’s worst eye, as adjusted for ungradable subjects.
RETeval
device
(this study)
Nonmydriatic
3-ﬁeld stereoscopic
photography
(Ahmed et al.,
2006; Bursell
et al., 2001)
Ophthalmologist
(Pugh et al., 1993)
Study sample size (n) 468 54 352
Sensitivity 87% 85% 33%
Speciﬁcity 78% 66% 99%
Positive Predictive Value 15% 10% 60%
Negative Predictive Value 99.2% 99.0% 97.0%
Per 1000 people
tested, expected
number of:
False positives 210 325 10
False negatives 6 7 29
True negatives 746 631 946
True positives 38 37 15
531A.Y. Maa et al. / Journal of Diabetes and Its Complications 30 (2016) 524–532RETeval device generates results even with small pupils (the smallest
pupil measured in this study was 1.4 mm). We believe that the
RETeval test can be performed easily in the primary care physician's
ofﬁce, or other locations where subjects with diabetes receive care or
obtain medications and supplies.
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